MENU
+Compare
ADIL
Stock ticker: NASDAQ
AS OF
Apr 24, 12:13 PM (EDT)
Price
$0.70
Change
-$0.00 (-0.00%)
Capitalization
4.46M

ADIL Adial Pharmaceuticals Forecast, Technical & Fundamental Analysis

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company... Show more

ADIL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ADIL with price predictions
Apr 23, 2025

ADIL's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for ADIL turned positive on April 23, 2025. Looking at past instances where ADIL's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ADIL advanced for three days, in of 202 cases, the price rose further within the following month. The odds of a continued upward trend are .

ADIL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 33 cases where ADIL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on April 22, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ADIL as a result. In of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

ADIL moved below its 50-day moving average on April 10, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADIL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.095) is normal, around the industry mean (14.056). P/E Ratio (0.000) is within average values for comparable stocks, (63.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.992).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ADIL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADIL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ADIL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ADIL is expected to report earnings to fall 81.25% to -5 cents per share on August 15

Adial Pharmaceuticals ADIL Stock Earnings Reports
Q2'23
Est.
$-0.06
Q4'24
Beat
by $0.05
Q1'23
Est.
$-0.10
Q4'22
Beat
by $0.05
Q3'22
Beat
by $0.06
The last earnings report on March 04 showed earnings per share of -31 cents, beating the estimate of -37 cents. With 4.53K shares outstanding, the current market capitalization sits at 4.46M.
A.I. Advisor
published General Information

General Information

a developer of medications to treat addiction and related disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
4870 Sadler Road
Phone
+1 804 487-8196
Employees
7
Web
https://www.adialpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DNUT4.480.20
+4.55%
Krispy Kreme
WLGS0.19N/A
+2.58%
Wang & Lee Group
ELA6.430.14
+2.23%
Envela Corp
KALV12.450.15
+1.22%
KalVista Pharmaceuticals
RNR239.96-3.54
-1.45%
RenaissanceRe Holdings Ltd

ADIL and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ADIL has been loosely correlated with SYRE. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ADIL jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADIL
1D Price
Change %
ADIL100%
+3.29%
SYRE - ADIL
39%
Loosely correlated
+1.86%
VANI - ADIL
37%
Loosely correlated
+1.86%
VTVT - ADIL
29%
Poorly correlated
+3.32%
BPMUF - ADIL
28%
Poorly correlated
N/A
GDTC - ADIL
27%
Poorly correlated
+2.83%
More